Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Next Previous
Trial Profile

Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Cangrelor (Primary) ; Tirofiban (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacodynamics

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Feb 2018 Planned End Date changed from 1 May 2018 to 29 May 2019.
    • 09 Feb 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top